These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 32090863)

  • 21. Repurposing-a ray of hope in tackling extensively drug resistance in tuberculosis.
    Maitra A; Bates S; Kolvekar T; Devarajan PV; Guzman JD; Bhakta S
    Int J Infect Dis; 2015 Mar; 32():50-5. PubMed ID: 25809756
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The potential role of trimethoprim-sulfamethoxazole in the treatment of drug-resistant tuberculosis.
    Palomino JC; Martin A
    Future Microbiol; 2016; 11(4):539-47. PubMed ID: 27070731
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Host-Directed Therapies: Modulating Inflammation to Treat Tuberculosis.
    Krug S; Parveen S; Bishai WR
    Front Immunol; 2021; 12():660916. PubMed ID: 33953722
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Managing TB in the 21st century: existing and novel drug therapies.
    Guy ES; Mallampalli A
    Ther Adv Respir Dis; 2008 Dec; 2(6):401-8. PubMed ID: 19124385
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of epigenetics, bacterial and host factors in progression of Mycobacterium tuberculosis infection.
    Marimani M; Ahmad A; Duse A
    Tuberculosis (Edinb); 2018 Dec; 113():200-214. PubMed ID: 30514504
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Statin adjunctive therapy shortens the duration of TB treatment in mice.
    Dutta NK; Bruiners N; Pinn ML; Zimmerman MD; Prideaux B; Dartois V; Gennaro ML; Karakousis PC
    J Antimicrob Chemother; 2016 Jun; 71(6):1570-7. PubMed ID: 26903278
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prospects for new antitubercular drugs.
    Duncan K; Barry CE
    Curr Opin Microbiol; 2004 Oct; 7(5):460-5. PubMed ID: 15451500
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recent advances for identification of new scaffolds and drug targets for Mycobacterium tuberculosis.
    Dhiman R; Singh R
    IUBMB Life; 2018 Sep; 70(9):905-916. PubMed ID: 29761628
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [EFFECT OF THE POLYENZYME DRUG WOBENZYM ON THE ACTIVITY OF A DESTRUCTIVE INFLAMMATORY PROCESS IN THE COMPLEX THERAPY OF PULMONARY TUBERCULOSIS].
    Yakimova AV; Ievlev-Duntau AP; Lipsky KA; Trunov AN; Shkurupiy VA
    Tuberk Biolezni Legkih; 2010; (6):47-51. PubMed ID: 27534056
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mycobacterium tuberculosis... Can we beat it? Report from a Euroscicon conference 2013.
    Maitra A; Bhakta S
    Virulence; 2013 Aug; 4(6):499-503. PubMed ID: 23863609
    [No Abstract]   [Full Text] [Related]  

  • 32. Why Wait? The Case for Treating Tuberculosis with Inhaled Drugs.
    Braunstein M; Hickey AJ; Ekins S
    Pharm Res; 2019 Oct; 36(12):166. PubMed ID: 31650321
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemotherapy of Tuberculosis.
    Dobbs TE; Webb RM
    Microbiol Spectr; 2017 Apr; 5(2):. PubMed ID: 28387179
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug repositioning for anti-tuberculosis drugs: an in silico polypharmacology approach.
    Madugula SS; Nagamani S; Jamir E; Priyadarsinee L; Sastry GN
    Mol Divers; 2022 Jun; 26(3):1675-1695. PubMed ID: 34468898
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vitamin C Potentiates the Killing of Mycobacterium tuberculosis by the First-Line Tuberculosis Drugs Isoniazid and Rifampin in Mice.
    Vilchèze C; Kim J; Jacobs WR
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29298757
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Priming the tuberculosis drug pipeline: new antimycobacterial targets and agents.
    Evans JC; Mizrahi V
    Curr Opin Microbiol; 2018 Oct; 45():39-46. PubMed ID: 29482115
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Host-Pathogen Interaction as a Novel Target for Host-Directed Therapies in Tuberculosis.
    Abreu R; Giri P; Quinn F
    Front Immunol; 2020; 11():1553. PubMed ID: 32849525
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Repurposing Approach for Uncovering the Anti-Tubercular Activity of FDA-Approved Drugs with Potential Multi-Targeting Profiles.
    Battah B; Chemi G; Butini S; Campiani G; Brogi S; Delogu G; Gemma S
    Molecules; 2019 Nov; 24(23):. PubMed ID: 31795400
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug resistance in Mycobacterium tuberculosis and targeting the l,d-transpeptidase enzyme.
    Gokulan K; Varughese KI
    Drug Dev Res; 2019 Feb; 80(1):11-18. PubMed ID: 30312987
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies.
    Tiberi S; du Plessis N; Walzl G; Vjecha MJ; Rao M; Ntoumi F; Mfinanga S; Kapata N; Mwaba P; McHugh TD; Ippolito G; Migliori GB; Maeurer MJ; Zumla A
    Lancet Infect Dis; 2018 Jul; 18(7):e183-e198. PubMed ID: 29580819
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.